Levofloxacin/prednisolone

Drug Profile

Levofloxacin/prednisolone

Alternative Names: DE 094; Levofloxacin/prednisolone A

Latest Information Update: 20 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Santen Pharmaceutical
  • Class Anti-inflammatories; Antiallergics; Antibacterials; Eye disorder therapies; Fluoroquinolones; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Infectious keratitis

Most Recent Events

  • 31 Jul 2010 Discontinued - Phase-II for Infectious keratitis in USA (Topical)
  • 20 Oct 2009 Levofloxacin/prednisolone is still in phase II trials for Infectious Keratitis in the US
  • 30 Jan 2008 Levofloxacin/prednisolone is still in phase II trials for Infectious keratitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top